The Pharma Job From Hell: Low Salary to Fix Sinking Giant Teva - Bloomberg
Kare Schultz, president and chief executive officer of Teva... Fotografía de noticias - Getty Images
Teva's Adderall Shortage Expected to Continue Into March, FDA Says - BNN Bloomberg
Análisis: Teva cae cerca de un 0,20% en el premarket | IG España
Teva Analysts Say Migraine Drug Approval Gives Needed Relief - Bloomberg
Teva's Adderall Shortage Seen Continuing Into March (TEVA) - Bloomberg
Teva considering cutting up to 10,000 jobs: Bloomberg
Drugmaker Teva Misled Court to Dodge Opioid Trial, New York State Claims - Bloomberg
Teva's Budding Blockbuster Drugs Lend Respite From Legal Concerns - Bloomberg
Teva Pharma's Short Sellers Double Down as Legal Woes Drag On - Bloomberg
Teva to Cut Up to 25% of Israel Workforce, Calcalist Says - Bloomberg
Teva Plunges as U.S. Sales Drop Amid Generic Price Erosion - Bloomberg
Teva Is Facing Adderall Supply Disruptions as Demand for ADHD Drug Soars - Bloomberg
Teva CEO Resigns; Dividend Cut Should Be Next - Bloomberg
Glaxo's Win in Case Against Teva Lifts Other Drugmakers - Bloomberg
Teva's CEO Was $2.8 Billion Down on His Second Day on the Job - Bloomberg
Teva Pharmaceutical Will Pay Over $4 Billion in Opioid Settlement - Bloomberg
Teva Pharmaceuticals Sued by U.S. Over Medicare Kickback Claims - BNN Bloomberg
Teva to Sell Assets Such as Women's Health Unit to Cut Debt - Bloomberg
Teva Considers 10,000 Job Cuts - Bloomberg
Teva Loses CEO, Leaving Investors to Guess What's Next - Bloomberg
Teva, Allergan ready to pay $5B to settle thousands of opioid lawsuits (TEVA) | Seeking Alpha
Teva shares jump in Tel Aviv after report of up to 10,000 job cuts | The Times of Israel
Teva Is Facing Adderall Supply Disruptions as Demand for ADHD Drug Soars - BNN Bloomberg
